Welcome to our dedicated page for Infusystem Hld SEC filings (Ticker: INFU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InfuSystem Holdings, Inc. filings document financial reporting, governance and material-event disclosures for a health care service provider focused on outpatient durable medical equipment services. Recent 8-K filings furnish earnings releases, conference-call announcements, investor presentations and Regulation FD disclosures tied to Patient Services and Device Solutions.
The company’s proxy materials cover board matters, shareholder voting, executive compensation and equity award disclosures. Other filings document accounting oversight, including changes in the independent registered public accounting firm, audits of consolidated financial statements and internal control over financial reporting.
InfuSystem Holdings Executive VP and CFO Barry G. Steele reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 17, 2026, 21,323 performance-based restricted stock units granted on May 17, 2024 vested and converted into common shares, increasing his holdings.
Across May 16–18, 2026, Steele exercised restricted stock units covering 7,511 and 8,715 shares of common stock and had 3,275, 9,297 and 3,800 shares withheld to satisfy tax liabilities tied to these vestings. Following these transactions, he directly owned 117,767 shares of InfuSystem common stock. Certain remaining restricted stock units are scheduled to vest in two equal annual installments beginning on May 16, 2027.
InfuSystem Holdings EVP-Chief HR Officer Jerod Funke reported compensation-related stock activity involving restricted stock units and associated tax withholding. On May 17, 2026, 14,570 performance-based restricted stock units granted on May 17, 2024 vested and converted into common stock on a one-for-one basis.
To cover tax liabilities from vesting and settlement on May 16–17, 2026, a total of 8,761 shares of common stock were withheld at $8.77 per share, which is reported as a disposition but is not an open-market sale. Funke’s direct common stock holdings increased to 36,116 shares after these transactions, and 10,363 restricted stock units remain outstanding, vesting in two equal annual installments beginning on May 16, 2027.
InfuSystem Holdings President and CEO Carrie Lachance reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 17, 2026, 21,855 performance-based restricted stock units granted on May 17, 2024 vested, converting into common stock on a one-for-one basis. On May 16 and May 18, she exercised restricted stock units covering 10,418 and 8,932 shares of common stock, respectively.
To cover tax liabilities from these vesting and settlement events, the issuer withheld 4,100 shares at $8.77, 5,322 shares at $8.77, and 3,515 shares at $8.90 per share. Following these transactions, Lachance directly holds 266,391 shares of common stock. Footnotes state that certain restricted stock units cliff vested on May 18, 2026, while others vest in two equal annual installments beginning May 17, 2027.
InfuSystem Holdings Executive VP and CIO Addam Chupa reported routine equity compensation activity involving restricted stock units and related tax withholding. On May 16, 2026, 4,375 restricted stock units converted into common stock on a one-for-one basis, with 1,602 shares withheld at $8.77 per share to cover tax liabilities. On May 17, 2026, 12,184 performance-based restricted stock units granted on May 17, 2024 vested, and 4,460 shares were withheld at $8.77 per share for taxes. On May 18, 2026, an additional 5,447 restricted stock units cliff vested and converted into common stock, with 1,994 shares withheld at $8.90 per share for tax obligations. Following these non-market transactions, Chupa directly held 61,160 shares of InfuSystem common stock.
InfuSystem Holdings, Inc. announced that its Board of Directors has approved a new stock repurchase program authorizing the Company to buy back up to $20 million of its outstanding common stock. The program will run from July 1, 2026 through June 30, 2028.
This new authorization will supersede the current repurchase program, which is scheduled to expire on June 30, 2026. Under the current authorization, InfuSystem repurchased approximately 1.6 million shares for about $11.9 million through March 31, 2026, reflecting ongoing use of buybacks as a capital allocation tool.
InfuSystem Holdings director Ronald T. Hundzinski received a stock option grant covering 24,890 shares of common stock. The option has an exercise price of $8.37 per share, vests on May 12, 2027, and expires on May 12, 2036. It represents a compensation-related award rather than an open-market purchase or sale. Following the reported transactions, Hundzinski holds 5,000 shares of InfuSystem common stock directly.
InfuSystem Holdings director Scott Shuda received a new stock option grant and reported his share holdings. He was granted options for 24,890 shares of common stock at an exercise price of $8.37 per share, expiring on May 12, 2036. The option represents the right to buy 24,890 shares and vests on May 12, 2027.
After these updates, Shuda holds 94,000 shares of common stock directly and 298,383 shares indirectly through Meridian OHC Partners, LP and BlueLine Capital Partners II, over which he has voting and dispositive power. He disclaims beneficial ownership of the shares held by Meridian and BlueLine for purposes of Rule 13d-3.
InfuSystem Holdings, Inc. director John J. Sviokla reported an equity compensation grant and his current shareholdings. He received stock options covering 24,890 shares of common stock at an exercise price of $8.37 per share. These options vest on May 12, 2027 and expire on May 12, 2036, giving him the right to buy shares in the future if conditions are met. The filing also shows he directly holds 10,000 shares of InfuSystem common stock following these transactions.
InfuSystem Holdings, Inc executive vice president and CIO Addam Chupa reported updated holdings and new equity awards. He now directly holds 47,210 shares of common stock, which the footnotes state includes 2,254 shares recently acquired through the company’s Employee Stock Purchase Plan.
On the same date, he received 9,973 restricted stock units that each convert into one share of common stock and 20,777 stock options with an exercise price of $8.37 per share. The options vest in four equal annual installments beginning on May 12, 2027, while the restricted stock units vest in three equal annual installments beginning on the same date.
InfuSystem Holdings director Beverly A. Huss reported an equity compensation grant. She received a stock option for 24,890 shares of common stock, with an exercise price of $8.37 per share. The option vests on May 12, 2027 and expires on May 12, 2036.
Following this grant, Huss holds 4,300 shares of common stock directly, along with the newly awarded options for 24,890 underlying shares. The filing reflects a compensation-related award rather than an open-market purchase or sale.